Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus(VRE): a systematic review
No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy. We perform...
Saved in:
| Published in | BMC infectious diseases Vol. 14; no. 1; p. 177 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central
31.03.2014
BioMed Central Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy.
We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012.
For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up.
Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. |
|---|---|
| AbstractList | Doc number: 177 Abstract Background: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy. Methods: We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012. Results: For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up. Conclusions: Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. Background: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy. Methods: We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012. Results: For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up. Conclusions: Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy. We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012. For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up. Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy.BACKGROUNDNo published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy.We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012.METHODSWe performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012.For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up.RESULTSFor MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up.Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up.CONCLUSIONSFew available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. BACKGROUND: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). Time to clearance of colonization has important implications for patient care and infection control policy. METHODS: We performed parallel searches in OVID Medline for studies that reported the time to documented clearance of MRSA and VRE colonization in the absence of treatment, published between January 1990 and July 2012. RESULTS: For MRSA, we screened 982 articles, identified 16 eligible studies (13 observational studies and 3 randomized controlled trials), for a total of 1,804 non-duplicated subjects. For VRE, we screened 284 articles, identified 13 eligible studies (12 observational studies and 1 randomized controlled trial), for a total of 1,936 non-duplicated subjects. Studies reported varying definitions of clearance of colonization; no study reported time of initial colonization. Studies varied in the frequency of sampling, assays used for sampling, and follow-up period. The median duration of total follow-up was 38 weeks for MRSA and 25 weeks for VRE. Based on pooled analyses, the model-estimated median time to clearance was 88 weeks after documented colonization for MRSA-colonized patients and 26 weeks for VRE-colonized patients. In a secondary analysis, clearance rates for MRSA and VRE were compared by restricting the duration of follow-up for the MRSA studies to the maximum observed time point for VRE studies (43 weeks). With this restriction, the model-fitted median time to documented clearance for MRSA would occur at 41 weeks after documented colonization, demonstrating the sensitivity of the pooled estimate to length of study follow-up. CONCLUSIONS: Few available studies report the natural history of MRSA and VRE colonization. Lack of a consistent definition of clearance, uncertainty regarding the time of initial colonization, variation in frequency of sampling for persistent colonization, assays employed and variation in duration of follow-up are limitations of the existing published literature. The heterogeneity of study characteristics limits interpretation of pooled estimates of time to clearance, however, studies included in this review suggest an increase in documented clearance over time, a result which is sensitive to duration of follow-up. |
| ArticleNumber | 177 |
| Author | Paras, Molly L Shenoy, Erica S Noubary, Farzad Hooper, David C Walensky, Rochelle P |
| AuthorAffiliation | 5 Division of Infectious Diseases, Infection Control Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 3 The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts Clinical and Translational Science Institute and Tufts University, Boston, MA, USA 1 Division of Infectious Diseases, Infection Control Unit and Medical Practice Evaluation Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 2 Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 4 Divisions of Infectious Diseases, Massachusetts General and Brigham and Women’s Hospital; Medical Practice Evaluation Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
| AuthorAffiliation_xml | – name: 1 Division of Infectious Diseases, Infection Control Unit and Medical Practice Evaluation Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA – name: 2 Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA – name: 3 The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts Clinical and Translational Science Institute and Tufts University, Boston, MA, USA – name: 5 Division of Infectious Diseases, Infection Control Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA – name: 4 Divisions of Infectious Diseases, Massachusetts General and Brigham and Women’s Hospital; Medical Practice Evaluation Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
| Author_xml | – sequence: 1 givenname: Erica S surname: Shenoy fullname: Shenoy, Erica S – sequence: 2 givenname: Molly L surname: Paras fullname: Paras, Molly L – sequence: 3 givenname: Farzad surname: Noubary fullname: Noubary, Farzad – sequence: 4 givenname: Rochelle P surname: Walensky fullname: Walensky, Rochelle P – sequence: 5 givenname: David C surname: Hooper fullname: Hooper, David C |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24678646$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1rGzEQXUpK89HeeyqCXpzDtvraldxDIRinLaQtJG2vQjvW1gq7kiNpHdw_kr9bOXZCHBooCGbQvHkz82YOiz3nnSmK1wS_I0TW7wkXpKSM8ZLkJ8Sz4uD-a--Bv18cxniJMRGSjl8U-5TXQta8Pihuvuk0BN2huY3JhxXyLQLfeWf_6GS9Q9c2zVFv0tyC7TrrymBihmqX0EXSi_mq8-ABhoj0EEw2o6_nFyfHSLsZWmoHvl_BTtbUJRO2OaNf59PjD0ijuIrJ9LkioGCW1ly_LJ63uovm1dYeFT9Ppz8mn8uz75--TE7OyqYiIpXjGQWJW44ZbmE2k8B5JTUVDJjUTSNo1bSAoQWg9RgaWoEYV1TWtWxaRivGjoqPG97F0PRmBsalrIZaBNvrsFJeW7UbcXaufvul4pRhTmUmmGwIGuufINiNZEXUejFqvZjsqby3zDLathH81WBiUr2NYLpOO-OHqEhFMZNjjqv_gJKq5oSJOkPfPoJe-iG4rOctCgvM6Lr2m4cS3Ld-dyQZUG8AEHyMwbQKbLq9jjyQ7RTBan2N_5oKP0q8434y5S_ne-Ri |
| CitedBy_id | crossref_primary_10_3390_ijerph15030479 crossref_primary_10_3390_plants14020259 crossref_primary_10_1016_j_jhin_2018_05_022 crossref_primary_10_5144_0256_4947_2018_200 crossref_primary_10_3390_antibiotics10040466 crossref_primary_10_1016_j_phytochem_2024_114355 crossref_primary_10_1128_aac_00903_22 crossref_primary_10_1080_07853890_2019_1662477 crossref_primary_10_1128_AAC_01338_15 crossref_primary_10_4103_0366_6999_198923 crossref_primary_10_3390_antibiotics13030214 crossref_primary_10_1038_s41598_019_48436_2 crossref_primary_10_1177_0969733017709335 crossref_primary_10_3389_fphar_2018_00619 crossref_primary_10_1093_ofid_ofv078 crossref_primary_10_3390_microorganisms11112804 crossref_primary_10_1093_ofid_ofw247 crossref_primary_10_3390_antibiotics11101361 crossref_primary_10_1017_ice_2016_229 crossref_primary_10_1371_journal_pone_0220684 crossref_primary_10_1007_s00134_016_4485_2 crossref_primary_10_1016_j_idc_2016_07_009 crossref_primary_10_3390_ijerph111212582 crossref_primary_10_1093_ofid_ofw133 crossref_primary_10_4103_ijhas_IJHAS_135_20 crossref_primary_10_1016_j_ajic_2020_06_219 crossref_primary_10_1017_ice_2020_176 crossref_primary_10_1093_cid_civ082 crossref_primary_10_1093_cid_ciy194 crossref_primary_10_12701_yujm_2019_00430 crossref_primary_10_2147_IDR_S340871 crossref_primary_10_1093_jac_dkae036 crossref_primary_10_1097_MD_0000000000023686 crossref_primary_10_3390_antibiotics10030227 crossref_primary_10_1016_j_ajic_2015_08_019 crossref_primary_10_1093_imammb_dqx010 crossref_primary_10_3390_biomedicines10102404 crossref_primary_10_1098_rsos_172341 crossref_primary_10_1186_s13099_018_0259_4 crossref_primary_10_1017_ice_2016_286 crossref_primary_10_1093_jacamr_dlad153 crossref_primary_10_1099_jmm_0_000731 crossref_primary_10_14192_kjnic_2015_20_1_19 crossref_primary_10_1007_s40592_020_00109_x crossref_primary_10_3390_microorganisms7100400 crossref_primary_10_1097_QCO_0000000000000244 crossref_primary_10_1007_s00103_018_2811_2 crossref_primary_10_1371_journal_pone_0197111 crossref_primary_10_1016_j_eimce_2017_01_001 crossref_primary_10_1093_cid_ciac070 crossref_primary_10_1016_j_jhin_2020_11_012 crossref_primary_10_2147_IDR_S296000 crossref_primary_10_1186_s13756_018_0390_5 crossref_primary_10_1017_ice_2017_245 crossref_primary_10_7554_eLife_68764 crossref_primary_10_1128_Spectrum_00356_21 crossref_primary_10_3390_molecules29194631 crossref_primary_10_3390_jcm9061757 crossref_primary_10_1186_s12941_019_0327_8 crossref_primary_10_1186_s13567_018_0563_5 crossref_primary_10_1186_s13756_018_0388_z crossref_primary_10_1016_j_jinf_2020_09_003 crossref_primary_10_1093_jtm_taac022 crossref_primary_10_3390_pathogens9070522 crossref_primary_10_1017_ice_2015_328 crossref_primary_10_1103_PhysRevResearch_6_023265 crossref_primary_10_2169_internalmedicine_6088_20 crossref_primary_10_3390_antibiotics10111366 crossref_primary_10_1016_j_jgar_2025_01_016 crossref_primary_10_1093_infdis_jiv597 crossref_primary_10_1097_MOG_0000000000000792 crossref_primary_10_1016_j_eimc_2016_12_001 crossref_primary_10_22246_jikm_2019_40_5_974 crossref_primary_10_1017_ice_2016_54 crossref_primary_10_1056_EVIDtt2300302 crossref_primary_10_1128_spectrum_02348_21 crossref_primary_10_1016_j_amjms_2018_08_015 crossref_primary_10_1177_0272989X17713474 crossref_primary_10_3390_ani12010085 crossref_primary_10_2807_1560_7917_ES_2019_24_38_1800676 crossref_primary_10_1039_D2MD00351A crossref_primary_10_1186_s12879_018_3028_6 crossref_primary_10_3390_antibiotics13080747 crossref_primary_10_1111_ejh_13151 crossref_primary_10_3390_antibiotics13080789 |
| Cites_doi | 10.1086/597296 10.1016/j.ajic.2012.02.001 10.1053/jhin.2000.0758 10.1086/502592 10.1017/S0950268810000099 10.1086/423965 10.1086/501871 10.1111/j.1532-5415.1998.tb02532.x 10.1086/322687 10.1128/JCM.41.12.5377-5383.2003 10.1086/317549 10.1086/520216 10.1086/593956 10.2307/30141910 10.1016/j.ajic.2008.04.257 10.1186/2047-2994-1-31 10.1016/j.ajic.2013.02.005 10.1086/502267 10.1086/320151 10.1093/cid/cit206 10.1016/j.ajic.2007.10.007 10.1093/jac/dkr204 10.1016/j.ajic.2010.06.024 10.1378/chest.115.4.1085 10.1086/658913 10.1086/510392 10.1086/661280 10.1001/archinternmed.2009.217 10.3201/eid1411.080337 10.1016/j.jhin.2010.05.022 10.1016/j.jhin.2006.12.014 10.1086/502036 10.1086/501968 10.1016/j.ajic.2007.10.006 10.1001/jama.290.14.1899 10.1016/S0002-9343(96)90007-8 10.1053/ic.1998.v26.a86286 10.3201/eid1312.070629 10.1086/520099 10.1086/502524 10.1086/519929 10.1086/668427 10.1086/510624 10.1086/502081 10.1136/bmj.b2535 10.1128/AAC.01590-09 10.1086/666629 10.1001/jama.1990.03450160053028 10.1093/clinids/19.6.1123 10.1056/NEJM200012283432604 10.1086/589582 10.1128/AAC.01086-06 10.1016/j.jhin.2011.04.011 10.1086/507917 |
| ContentType | Journal Article |
| Copyright | 2014 Shenoy et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Copyright © 2014 Shenoy et al.; licensee BioMed Central Ltd. 2014 Shenoy et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: 2014 Shenoy et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. – notice: Copyright © 2014 Shenoy et al.; licensee BioMed Central Ltd. 2014 Shenoy et al.; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1186/1471-2334-14-177 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 177 |
| ExternalDocumentID | PMC4230428 oai_biomedcentral_com_1471_2334_14_177 3272656921 24678646 10_1186_1471_2334_14_177 |
| Genre | Research Support, Non-U.S. Gov't Systematic Review Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Massachusetts |
| GeographicLocations_xml | – name: Massachusetts |
| GrantInformation_xml | – fundername: PHS HHS grantid: T32 A107061 – fundername: NCATS NIH HHS grantid: 8UL1TR000170-05 – fundername: NCRR NIH HHS grantid: 1 UL1RR02578 – fundername: NCRR NIH HHS grantid: UL1 RR025758 – fundername: NIAID NIH HHS grantid: K01 AI110524 – fundername: NCATS NIH HHS grantid: UL1 TR000170 – fundername: NIAID NIH HHS grantid: T32 AI007061 – fundername: NIAID NIH HHS grantid: P30 AI060354 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7QL 7T2 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 -A0 ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM |
| ID | FETCH-LOGICAL-b517t-9d2c80f4030fcdd8c4458a273c38abb725bfc0cfcc269cb25c79528668bf32533 |
| IEDL.DBID | RBZ |
| ISSN | 1471-2334 |
| IngestDate | Thu Aug 21 14:05:43 EDT 2025 Wed May 22 07:13:16 EDT 2024 Fri Jul 11 05:44:50 EDT 2025 Fri Jul 11 05:50:11 EDT 2025 Fri Jul 25 02:31:12 EDT 2025 Wed Jul 30 01:46:16 EDT 2025 Tue Jul 01 01:57:09 EDT 2025 Thu Apr 24 22:54:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://www.springer.com/tdm This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b517t-9d2c80f4030fcdd8c4458a273c38abb725bfc0cfcc269cb25c79528668bf32533 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | http://dx.doi.org/10.1186/1471-2334-14-177 |
| PMID | 24678646 |
| PQID | 1515070327 |
| PQPubID | 42582 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230428 biomedcentral_primary_oai_biomedcentral_com_1471_2334_14_177 proquest_miscellaneous_1520389405 proquest_miscellaneous_1515641376 proquest_journals_1515070327 pubmed_primary_24678646 crossref_citationtrail_10_1186_1471_2334_14_177 crossref_primary_10_1186_1471_2334_14_177 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-03-31 |
| PublicationDateYYYYMMDD | 2014-03-31 |
| PublicationDate_xml | – month: 03 year: 2014 text: 2014-03-31 day: 31 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2014 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | HR Day (3124_CR54) 2011; 39 MW Ellis (3124_CR15) 2004; 39 EM D’Agata (3124_CR32) 2001; 32 C Brennen (3124_CR28) 1998; 46 MR Vriens (3124_CR17) 2005; 26 LO Conterno (3124_CR52) 2007; 65 JD Siegel (3124_CR41) 2007; 35 MW Ellis (3124_CR19) 2007; 51 CJ Donskey (3124_CR45) 2002; 23 TZ Cretnik (3124_CR16) 2005; 26 A Robicsek (3124_CR23) 2009; 48 E Iosifidis (3124_CR47) 2013; 41 M Greenwood (3124_CR8) 1926; 33 MA Montecalvo (3124_CR27) 1995; 16 EM Mascini (3124_CR36) 2003; 41 E Lautenbach (3124_CR24) 2010; 138 JC Lucet (3124_CR22) 2009; 169 BN Doebbeling (3124_CR50) 1990; 264 JD Siegel (3124_CR40) 2007; 35 YK Yoon (3124_CR39) 2011; 66 AE Simor (3124_CR20) 2007; 44 WR Jarvis (3124_CR1) 2012; 40 I Park (3124_CR38) 2011; 79 A Bhalla (3124_CR43) 2003; 24 NR O’Sullivan (3124_CR13) 2000; 45 SM Bhorade (3124_CR30) 1999; 115 ES Shenoy (3124_CR49) 2012; 33 MT Wong (3124_CR33) 2001; 33 T Kim (3124_CR51) 2001; 22 GA Wells (3124_CR9) 2014 SS Huang (3124_CR37) 2007; 195 MD Zilberberg (3124_CR2) 2008; 14 C Wendt (3124_CR21) 2007; 28 A Manzur (3124_CR25) 2010; 76 ES Shenoy (3124_CR5) 2012; 33 PL Mulhausen (3124_CR12) 1996; 100 CJ Donskey (3124_CR42) 2000; 343 DJ Morgan (3124_CR53) 2009; 37 AM Goetz (3124_CR29) 1998; 26 R Hachem (3124_CR35) 2002; 23 KE Byers (3124_CR34) 2002; 23 M Drees (3124_CR44) 2008; 29 EV van Velzen (3124_CR26) 2011; 32 HT Stelfox (3124_CR6) 2003; 290 A McLemore (3124_CR55) 2011; 32 S Karki (3124_CR46) 2012; 1 LO Conterno (3124_CR7) 2007; 28 MD Sanford (3124_CR11) 1994; 19 AD Harris (3124_CR56) 2010; 54 AM Ramsey (3124_CR3) 2009; 30 A Scanvic (3124_CR14) 2001; 32 E Klein (3124_CR4) 2007; 13 D Moher (3124_CR10) 2009; 339 MR Weinstein (3124_CR31) 1999; 29 J Marschall (3124_CR18) 2006; 27 ES Shenoy (3124_CR48) 2013; 57 |
| References_xml | – volume: 48 start-page: 910 issue: 7 year: 2009 ident: 3124_CR23 publication-title: Clin Infect Dis doi: 10.1086/597296 – volume: 40 start-page: 194 issue: 3 year: 2012 ident: 3124_CR1 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2012.02.001 – volume: 45 start-page: 322 issue: 4 year: 2000 ident: 3124_CR13 publication-title: J Hosp Infect doi: 10.1053/jhin.2000.0758 – volume: 26 start-page: 629 issue: 7 year: 2005 ident: 3124_CR17 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/502592 – volume: 138 start-page: 683 issue: 5 year: 2010 ident: 3124_CR24 publication-title: Epidemiol Infect doi: 10.1017/S0950268810000099 – volume: 39 start-page: 971 issue: 7 year: 2004 ident: 3124_CR15 publication-title: Clin Infect Dis doi: 10.1086/423965 – volume: 22 start-page: 99 issue: 2 year: 2001 ident: 3124_CR51 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/501871 – volume: 46 start-page: 157 issue: 2 year: 1998 ident: 3124_CR28 publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.1998.tb02532.x – volume: 33 start-page: 1476 issue: 9 year: 2001 ident: 3124_CR33 publication-title: Clin Infect Dis doi: 10.1086/322687 – volume: 41 start-page: 5377 issue: 12 year: 2003 ident: 3124_CR36 publication-title: J Clin Microbiol doi: 10.1128/JCM.41.12.5377-5383.2003 – volume: 32 start-page: 23 issue: 1 year: 2001 ident: 3124_CR32 publication-title: Clin Infect Dis doi: 10.1086/317549 – volume: 29 start-page: 361 issue: 2 year: 1999 ident: 3124_CR31 publication-title: Clin Infect Dis doi: 10.1086/520216 – volume: 30 start-page: 184 issue: 2 year: 2009 ident: 3124_CR3 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/593956 – volume: 16 start-page: 680 issue: 12 year: 1995 ident: 3124_CR27 publication-title: Infect Control Hosp Epidemiol doi: 10.2307/30141910 – volume: 37 start-page: 85 issue: 2 year: 2009 ident: 3124_CR53 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2008.04.257 – volume: 1 start-page: 31 issue: 1 year: 2012 ident: 3124_CR46 publication-title: Antimicrob Resist Infect Control doi: 10.1186/2047-2994-1-31 – volume: 41 start-page: 857 issue: 10 year: 2013 ident: 3124_CR47 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2013.02.005 – volume: 24 start-page: 644 issue: 9 year: 2003 ident: 3124_CR43 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/502267 – volume: 32 start-page: 1393 issue: 10 year: 2001 ident: 3124_CR14 publication-title: Clin Infect Dis doi: 10.1086/320151 – volume: 57 start-page: 176 issue: 2 year: 2013 ident: 3124_CR48 publication-title: Clin Infect Dis doi: 10.1093/cid/cit206 – volume: 35 start-page: S65 issue: 10 Suppl 2 year: 2007 ident: 3124_CR40 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2007.10.007 – volume: 66 start-page: 1831 issue: 8 year: 2011 ident: 3124_CR39 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr204 – volume: 39 start-page: 163 issue: 2 year: 2011 ident: 3124_CR54 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2010.06.024 – volume-title: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses year: 2014 ident: 3124_CR9 – volume: 115 start-page: 1085 issue: 4 year: 1999 ident: 3124_CR30 publication-title: Chest doi: 10.1378/chest.115.4.1085 – volume: 32 start-page: 298 issue: 3 year: 2011 ident: 3124_CR55 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/658913 – volume: 44 start-page: 178 issue: 2 year: 2007 ident: 3124_CR20 publication-title: Clin Infect Dis doi: 10.1086/510392 – volume: 32 start-page: 889 issue: 9 year: 2011 ident: 3124_CR26 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/661280 – volume: 169 start-page: 1372 issue: 15 year: 2009 ident: 3124_CR22 publication-title: Arch Intern Med doi: 10.1001/archinternmed.2009.217 – volume: 33 start-page: 1 year: 1926 ident: 3124_CR8 publication-title: Rep Public Health Med Subj – volume: 14 start-page: 1756 issue: 11 year: 2008 ident: 3124_CR2 publication-title: Emerg Infect Dis doi: 10.3201/eid1411.080337 – volume: 76 start-page: 215 issue: 3 year: 2010 ident: 3124_CR25 publication-title: J Hosp Infect doi: 10.1016/j.jhin.2010.05.022 – volume: 65 start-page: 354 issue: 4 year: 2007 ident: 3124_CR52 publication-title: J Hosp Infect doi: 10.1016/j.jhin.2006.12.014 – volume: 23 start-page: 207 issue: 4 year: 2002 ident: 3124_CR34 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/502036 – volume: 23 start-page: 43 issue: 1 year: 2002 ident: 3124_CR35 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/501968 – volume: 35 start-page: S165 issue: 10 Suppl 2 year: 2007 ident: 3124_CR41 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2007.10.006 – volume: 290 start-page: 1899 issue: 14 year: 2003 ident: 3124_CR6 publication-title: JAMA doi: 10.1001/jama.290.14.1899 – volume: 100 start-page: 24 issue: 1 year: 1996 ident: 3124_CR12 publication-title: Am J Med doi: 10.1016/S0002-9343(96)90007-8 – volume: 26 start-page: 558 issue: 6 year: 1998 ident: 3124_CR29 publication-title: Am J Infect Control doi: 10.1053/ic.1998.v26.a86286 – volume: 13 start-page: 1840 issue: 12 year: 2007 ident: 3124_CR4 publication-title: Emerg Infect Dis doi: 10.3201/eid1312.070629 – volume: 28 start-page: 1134 issue: 10 year: 2007 ident: 3124_CR7 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/520099 – volume: 26 start-page: 184 issue: 2 year: 2005 ident: 3124_CR16 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/502524 – volume: 28 start-page: 1036 issue: 9 year: 2007 ident: 3124_CR21 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/519929 – volume: 33 start-page: 1272 issue: 12 year: 2012 ident: 3124_CR49 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/668427 – volume: 195 start-page: 339 issue: 3 year: 2007 ident: 3124_CR37 publication-title: J Infect Dis doi: 10.1086/510624 – volume: 23 start-page: 436 issue: 8 year: 2002 ident: 3124_CR45 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/502081 – volume: 339 start-page: b2535 year: 2009 ident: 3124_CR10 publication-title: BMJ doi: 10.1136/bmj.b2535 – volume: 54 start-page: 3143 issue: 8 year: 2010 ident: 3124_CR56 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01590-09 – volume: 33 start-page: 849 issue: 8 year: 2012 ident: 3124_CR5 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/666629 – volume: 264 start-page: 2083 issue: 16 year: 1990 ident: 3124_CR50 publication-title: JAMA doi: 10.1001/jama.1990.03450160053028 – volume: 19 start-page: 1123 issue: 6 year: 1994 ident: 3124_CR11 publication-title: Clin Infect Dis doi: 10.1093/clinids/19.6.1123 – volume: 343 start-page: 1925 issue: 26 year: 2000 ident: 3124_CR42 publication-title: N Engl J Med doi: 10.1056/NEJM200012283432604 – volume: 29 start-page: 709 issue: 8 year: 2008 ident: 3124_CR44 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/589582 – volume: 51 start-page: 3591 issue: 10 year: 2007 ident: 3124_CR19 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01086-06 – volume: 79 start-page: 147 issue: 2 year: 2011 ident: 3124_CR38 publication-title: J Hosp Infect doi: 10.1016/j.jhin.2011.04.011 – volume: 27 start-page: 1206 issue: 11 year: 2006 ident: 3124_CR18 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/507917 |
| SSID | ssj0017829 |
| Score | 2.3720965 |
| SecondaryResourceType | review_article |
| Snippet | No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or... Doc number: 177 Abstract Background: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant... Background: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or... BACKGROUND: No published systematic reviews have assessed the natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) or... |
| SourceID | pubmedcentral biomedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 177 |
| SubjectTerms | Carrier State - microbiology Disease control Enterococcus Gram-Positive Bacterial Infections - microbiology Hospitals Humans Long term health care Medical practices Medical schools Methicillin-Resistant Staphylococcus aureus - physiology Reporting requirements Staphylococcal Infections - microbiology Staphylococcus aureus Staphylococcus infections Statistical methods Studies Vancomycin-Resistant Enterococci - physiology |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dSxwxEA9WofRFWvt1aksKffAewrnZbJIthSJFkcL5YGu5t5BMdmnB7qp39-B_4p_rzH6cXVuFgz1Ihv2YSeY3yeQ3jH00wRQI64NQMmKAonIrfLS05ypBpSlkpkn5n57o4zP1bZbNugW3eZdW2c-JzUQda6A18gk5XjJPab5cXAqqGkW7q10JjSdsg6jLKKXLzFYBV4LeL--3Jq2eJDgRC5mmSiT4M-beGffzoWv6B2_eT5v8yw8dPWebHYDkB63GX7C1otpiT6fdFvlLdnPiGyoN3jIJX_O65MRM3R-45LTyyqlwNAoQIbfAgJtAZLXgiDzxq6N7qwGWc-6XVwVe9qan3w_G3FeRU75A_ecaBlJNXkEvs_fz9HD8iXt-RxHN2-Mxr9jZ0eGPr8eiK78gQpaYhcijBLtfKpwGSojRglKZ9Qh3ILU-BCOzUMI-lABS5xBkBibPpNXahjKVCCNfs_Wqroq3jOvoJUbtOgnWKJ9o70NaaoyIy8LnQcYR-zzQhLtoqTYckV8PW_AtHSnSkSLxn0NFjtikV5yDjtqcKmycuybEsfo_EuOVRH-vh_vu9rbgugE-d3fmOGIfVs04NGm_xVdFvWz7aAQJRj_WRxLFIcLmEXvTmtfqgSQ6MasVSpuB4Q2-zrCl-v2roQhXtNYv7fbjj77DniH-U-0Ry122vrhaFu8QYy3C-2Yg3QKgkCoL priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swELcGSIiXaeOzjE2exEP7EEocx3YQ04QmEEIqD4Ui3izbSQRSl0BpJfqf7M_dXT7aBbpKkRLJPuXjfL7f5Xw_E3IorUwA1luPsxgCFB4pz8QKc67M8SBwoSyW_PeuxeWAX92H9_Py6OoDviwM7XA_qcFoePT6PP0JBv-jMHgluj5MsB4LAu75cEi5QtbAL0k00x6f5xTAF0Z1onKB1JuK92HTUb1Dn28XUf7jlS4-kY8VnKRnpf4_kw9JtknWe1XCfIv8uTYFsQYteYWnNE8p8lTX5ZcU_8NS3EYaBJCe24PwGyFlNqaAQ0EH4Oxy5yYv1ExGCZzavf7NWYeaLKa4eiD_PXUNqWKVQS3Tvuufd06ooXPCaFoWy2yTwcX57a9Lr9qMwbOhL8deFDOnjlMOk0Lq4lg5zkNlAPy4QBlrJQtt6o5d6hwTkbMsdDIKmRJC2TRgACp3yGqWZ8keoSI2DGJ44VslufGFMTZIBcTHaWIiy-IWOW1oQj-VxBsaqbCbLfCWGhWpUZFwpUGRLdKtFaddRXSO-20MdRHwKLFAojOTqO_1_74H9VjQ9WjViApx7mTQ_H3WDIaK2ReTJfmk7CMAMkixrA9DwkMA0S2yWw6v2QMxcGlKcJCWjYHX-DrNluzxoSAM5_jnn6n95Y_-hWwAGuRlweUBWR2PJslXQFxj-60wpL9yniyY priority: 102 providerName: Scholars Portal |
| Title | Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus(VRE): a systematic review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24678646 https://www.proquest.com/docview/1515070327 https://www.proquest.com/docview/1515641376 https://www.proquest.com/docview/1520389405 http://dx.doi.org/10.1186/1471-2334-14-177 https://pubmed.ncbi.nlm.nih.gov/PMC4230428 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED8NkKa9TGNflEFlpD3QhwjiOLYz8QKoCCG1mroxVXuxbCfRJkEyQfvAf8Kfu7t8FFI-XpCqNJJ9Seuzfb_z-X4G-KqcyhDWu0DwFB0UkejApppirtyLKPKxqrb8j8by9FycTePpHU3OUgQ_1HIvxOkz4FEkghA_Sq3AGhdoB8kzP_q9iBigpUuqTKKmdhuSfOQJS7ntF12T9ABnLm-XvGd_Tt7B2wY4ssNa0-vwKivew-tRExr_ALdjW1FosJpB-IaVOSNG6jbRktGKK6MDo1GAiLgDdLQJPBYzhogTWxvNWun9_JrZ-VWGX7ujyY_DAbNFymifQHl54ztS1X6CVmb312Q4-MYsu6OGZnVazEc4Pxn-PD4NmmMXAheHahYkKfd6Pxc4_HOfptoLEWuLMMdH2jqneOxyv-9z77lMvOOxV0nMtZTa5RFH-PgJVouyyDaAydRy9NZl6LQSNpTWuiiX6AnnmU0cT3tw0NGE-VdTbBgive6W4L80pEhDisQ7g4rswV6rOOMbSnM6WePCVK6Nlo9IDBYS7buerrvV9gXTDOxrQ_iPZkmOxTuLYhySFGexRVbO6zoSwYGSz9XhRG2IcLkHn-vutfhBHI2XlgKlVafjdVqnW1L8_VNRgwta4-d682Xt-gXeIC4UderlFqzOrubZNmKvmevDipoqvOrjsA9rR8Px90m_WsfA60jofjUo_wPDnzIy |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIQEviG8KA4wE0voQtXEc20EgNMGmjq19GBvqm-ePRCCNZKytUP8T_gr-Ru6SuCMD9japUivZp6a983347n5HyEtpZQ5uvY048xCg8ExFxivMuTLHk8Slsi75H0_E6Ih_nKbTNfIr9MJgWWXQibWi9pXDO_IBGl4UTybfnX6PcGoUZlfDCI1GLPby5Q8I2WZvdz8Af18xtrN9-H4UtVMFIpvGch5lnjk1LDhId-G8V47zVBmw4i5RxlrJUlu4oSucYyJzlqVOZilTQihbJCzFC1BQ-dfA8A7xRMnpKsCLwdpmIRWqxCAGxR-xJOFRDC8pL_TUn3RN4V_-7cUyzT_s3s5tcqt1WOlWI2F3yFpe3iXXx21K_h75OTE1dAdtkIuXtCooImGHBk-KN70UB1UDAQKARxDgo9Nazil4usBlMKeVc4sZNYuzHN42xweftvrUlJ5ifUL1bek6VHUdQ6DZ_Hyw3X9NDT2HpKZNO859cnQljHlA1suqzB8RKrxhuU1EbJXkJhbG2KQQEIEXucks8z3ypsMJfdpAe2gE2-6uwK_UyEiNjIRPGhjZI4PAOO1aKHWc6HGi65BKiX9Q9FcU4bv-v3cjyIJuFcpMn4t_j7xYLYMqwPyOKfNq0ewR4JRIcdkehpCK4Kb3yMNGvFYPxMBoKsGBWnYEr_PvdFfKr19qSHKOuQWmHl_-6M_JjdHheF_v7072npCb4Hvypr1zg6zPzxb5U_Dv5vZZfagoOb7qU_wb5JVnEA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELe2IU28IL4pDDASD-tD6OL4K4iXAas2oBUqDE28WPY5EYgundb2Yf8Jfy5nJynLGHuZVKmR7Gva3Nn3u97dz4S8VE4VCOtdwpnHAIXnOrFeh5wrA55lIFQs-R-N5f4h_3AkjtbIpO2FccfQViEt502OYv7qfCv6NO7feAG_Bie-rJe9loMUt9mEZRlPUnwptU5uKCFUWKyTt99XmQX0iHnsOGpmt6nLSz7hQg_8tOu6_sGjF8sqz_mp4W1yqwGYdLe2iDtkrajuks1Rk0K_R36PbaTaoDXT8BmdlTQwV7cNmTT8M0vDwdIoEAi7EwzIA8isFhSRKWoF3d8MYDmndnla4Nv2aPJlt09t5WmoJ5gdn0FHKtYdtDLb3yZ7_dfU0r8U0rRun7lPDod7X9_tJ83xDIkTqVokuWegd0qO20QJ3mvgXGiLcAgybZ1TTLgSdqAEYDIHxwSoXDAtpXZlxhBmPiAb1awqHhEqvWUY1cvUacVtKq11WSkxYi4Lmzvme-RNRxPmpKbiMIEcuzuCv9IERZqgSLwyqMgeGbSKM9BQn4cTOKYmhkBaXiLRX0m09_r_3K3WFkyzAcxNwIlhN2U4_GI1jEs35GNsVaB1xzkSQYSSV81hgQIRYXWPPKzNa_WFGDo5LTlKq47hdZ5Od6T6-SNSiPOQC2D68fWe63Oy-fn90Hw6GH98Qm4ilOR1t-YW2VicLounCNcW7llcf38AeKw_5g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+history+of+colonization+with+methicillin-resistant+Staphylococcus+aureus+%28MRSA%29+and+vancomycin-resistant+Enterococcus+%28VRE%29%3A+a+systematic+review&rft.jtitle=BMC+infectious+diseases&rft.au=Shenoy%2C+Erica+S&rft.au=Paras%2C+Molly+L&rft.au=Noubary%2C+Farzad&rft.au=Walensky%2C+Rochelle+P&rft.date=2014-03-31&rft.pub=BioMed+Central&rft.eissn=1471-2334&rft.volume=14&rft_id=info:doi/10.1186%2F1471-2334-14-177&rft.externalDocID=3272656921 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |